Charlie Rowand

On November 2, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) announced the successful completion of their end-of-Phase II meeting with the FDA and plans for a single Phase III clinical trial for fast-track-designated Voclosporin. Shares are up over 30 percent since then. There are an estimated 115,000...